Ilyashev & Partners Initiates Safeguard Investigation into Syringe Imports into Ukraine

Ilyashev & Partners Initiates Safeguard Investigation into Syringe Imports into Ukraine

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Acting on behalf of Hemoplast PJSC, Ilyashev & Partners has persuaded Ukraine's Interdepartmental International Trade Commission to initiate a safeguard investigation into syringe imports to Ukraine regardless of the country of origin or export, which the firm says "protects the interests of all Ukrainian syringe manufacturers."

Hemoplast PJSC is a Ukrainian manufacturer of medical products, including, primarily, disposable syringes and devices for blood and solution transfusion. In addition, it produces catheters, probes, and medical and laboratory products, as well as hundreds of non-medical plastic goods. The company was founded in 1973.

Depending upon the outcome of the investigation Ukraine may apply a safeguard duty or set a quota for the import of goods into Ukraine to prevent or eliminate serious damage to its economy. The safeguard investigation will take from 9 to 12 months.

“At the moment we are actively participating in the investigation conducted by the Ministry for Development of Economy, Trade and Agriculture of Ukraine, proving a serious damage to the domestic industry from the growing imports," said Olena Omelchenko, the Partner and Head of International Trade at Ilyashev & Partners, who is leading the firm's team on the matter. "We will provide all the information required to protect both the national producers and the consumers."

Ironically, just last year, acting on behalf of a foreign producer of syringes (India's Lifelong Meditech Private Limited), Ilyashev & Partners successfully persuaded the Interdepartmental International Trade Commission that it need take no measures against its client following an anti-dumping investigation on imports into Ukraine of syringes originating from the Republic of India, the Republic of Turkey, and the People’s Republic of China that had been initiated by Hemoplast and Tyumen-Mediko-Smila Private JSC.